Clearside's ocular oncology partner, Aura Biosciences, is enrolling patients in its global Phase 3 CoMpass trial evaluating belzupacap sarotalocan (bel-sar) for the first-line treatment of adult ...

BOSTON, March 23, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ ... statements concerning the timing, conduct and results of the TransCode's clinical trials, statements about microRNAs ...

About TransCode Therapeutics TransCode is a clinical ... statements concerning the timing, conduct and results of the Phase 1 clinical trial, statements about microRNAs and their involvement ...

Watch the video above to see the full episode of Catalysts from March 6, 2025. To watch more expert insights and analysis on ...

About TransCode Therapeutics TransCode is a clinical-stage ... statements concerning the timing, conduct and results of the Phase 1 clinical trial, statements about microRNAs and their involvement ...

SAN FRANCISCO - Nektar Therapeutics (NASDAQ ... followed by Canada and the United States, were enrolled based on their alopecia severity. InvestingPro data shows the company maintains a strong ...

The study was conducted across 21 sites, 19 of them in the United ... conduct of the study. Dr Morgan reported receiving grants from University of Florida, Cerevance, Cerevel, Intracellular ...

The Sports Business Journal reports that the San Francisco Giants have sold about 10% of the team to private equity group ...

Celanese Corporation ("Celanese"), a global chemical and specialty materials company, today announced the early results of offers by its direct wholly-owned subsidiary Celanese US Holdings LLC (the ...

Home sellers who did not list their properties on the Multiple Listing Service (MLS) ? a database that allows listings to be openly marketed to all home buyers and agents ? lost out on more than $1 ...

The line between science fiction and reality is blurring at an astonishing pace, as evidenced by groundbreaking research from ...